Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections – SMART United States 2018–2019

Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections – SMART United States 2018–2019

Abstract Background Ceftolozane/tazobactam (C/T) is approved in 70 countries, including the United States, for the treatment of patients with hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible Gram-negative pathogens. C/T is of particular importance as an agent for...

Full description

Bibliographic Details
Main Authors: James A. Karlowsky, Sibylle H. Lob, Katherine Young, Mary R. Motyl, Daniel F. Sahm
Format: Article
Language:English
Published: BMC 2021-03-01
Series:BMC Microbiology
Subjects:
Ceftolozane/tazobactam
Enterobacterales
Pseudomonas aeruginosa
United states
SMART
Surveillance
Online Access:https://doi.org/10.1186/s12866-021-02135-z

Similar Items

Similar Items